 | Up a level |
Burkhard, J; Ciurea, A; Gabay, C; Hasler, P; Müller, R; Niedrig, M; Fehr, J; Villiger, P; Visser, L G; de Visser, A W; Walker, U A; Hatz, C; Bühler, S (2020). Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Vaccine, 38(19), pp. 3610-3617. Elsevier 10.1016/j.vaccine.2019.12.042
Meier, FM; Frommer, KW; Dinser, R; Walker, UA; Czirjak, L; Denton, CP; Allanore, Y; Distler, O; Riemekasten, G; Valentini, G; Müller-Ladner, U; Matucci-Cerinic, M; Guiducci, S; Tyndall, A; Lapadula, G; Iannone, F; Becvar, R; Sierakowsky, S; Kowal-Bielecka, O; Cutolo, M; ... (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the rheumatic diseases, 71(8), pp. 1355-1360. London: BMJ Publishing Group 10.1136/annrheumdis-2011-200742
Beglinger, C; Dudler, J; Mottet, C; Nicod, L; Seibold, F; Villiger, P; Zellweger, J (2007). Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss medical weekly(137), 620-2 A. Muttenz: EMH Schweizerischer Ärzteverlag
